Combination comprising an HMG-CoA reductase inhibitor and an insulin secretor enhancer or an insulin sensitizer

摘要

Claim 1: a combination of at least two components selected from the group consisting of: (i) an HMG CoA reductase inhibitor or a pharmaceutically acceptable Salt thereof, selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, L Ovastatina, pitavastatin, pravastatin, rosuvastatin,And simvastatin; and (ii) a potentiating insulin secretion or a pharmaceutically acceptable Salt thereof; or (b) an insulin Sensitizing or a pharmaceutically acceptable Salt thereof.Claim 2: a combination of at least two components selected from the group consisting of: (i) an HMG CoA reductase inhibitor or a pharmaceutically acceptable Salt thereof; and (ii) a potentiating insulin secretion or a pharmaceutically acceptable Salt The Same,Selected from the group consisting of: tolbutamide chlorpropamide tolazamide acetohexamide,;;; glicopiramida; Glibenclamide; Gliclazide; 1 - butyl - 4 - metanilurea; carbutamide; glibonurida; glipizide; gliquidone; glisoxepide glybuthiazol glybuzole glyhexamide;;;; glimidina glypinamide; fenbutam; Ida; tolilciclamida, nateglinide, repaglinide, mitiglinide, glimepiride, dpp-iv Inhibitors, GLP1,GLP1, glp-1 (7 36); gln.sup.9-glp-1 (7 - 37); d-gln.sup.9-glp-1 (7 - 37); acetil-lys-sup.9-glp-1 (7 - 37); thr.sup.16-lys.sup.18-glp-1 (7 - 37); and lys.sup.18-glp-1 (7 - 37); or (b) an insulin Sensitizing or a pharmaceutically acceptable Salt thereof.A combination of claim 10: According to claim 1, wherein: (a) the Enhancer of insulin secretion or a pharmaceutically acceptable Salt thereof is nateglinide or a pharmaceutically acceptable Salt of the same; or (b) Sensitizing insulin secretion and S Metformin.